2025 marked a transformative year with FDA approval and US launch of a partner's product using proprietary technology, a 10-year agreement securing future revenues, and strengthened finances for expansion. Net sales declined, but operating losses narrowed and cash position improved.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.